Research programme: open angle glaucoma therapeutics - Editas Medicine
Alternative Names: CRISPR/Cas12a LNP - Editas; LNP AsCas12a - Editas MedicineLatest Information Update: 24 May 2024
At a glance
- Originator Editas Medicine
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Open-angle glaucoma